ZDHHC8 (ZDHHC Palmitoyltransferase 8) is a key gene that regulates cancer cell proliferation and is a potential therapeutic target. It is linked to a poor prognosis and is markedly overexpressed in many malignancies, including chronic lymphocytic leukemia (CLL). However, its pathogenic mechanism in CLL remains unclear. To identify important genes, RNA sequencing data from the Gene Expression Omnibus (GEO) collection were analyzed for differential expression. Subsequently, machine learning methods were employed to prioritize the core candidate genes. Additionally, important metabolic pathways were identified using Gene Set Enrichment Analysis (GSEA). Furthermore, protein-protein interaction (PPI) studies were used to identify the downstream targets of the core genes. Mendelian randomization (MR) analysis was used to investigate the regulatory mechanisms of CLL’s core genes. ZDHHC8 expression was markedly elevated in CLL patients and was linked to a poor prognosis. CAV1 is a key downstream target of ZDHHC8 in regulating CLL proliferation and anti-apoptosis. Mechanistically, ZDHHC8 expression grouping-based GSEA showed a notable enrichment of cellular lipid metabolism pathways, indicating that this is a major mechanism by which ZDHHC8 facilitates the development of CLL. MR analysis revealed substantial evidence of a positive causal connection between increased CAV1 expression and increased lipid metabolism. Further research has revealed that ZDHHC8 palmitoylates CAV1, activating cellular lipid metabolism to supply energy to cancer cells and driving the proliferation of malignant CLL.This work investigates the method by which ZDHHC8 regulates lipid metabolism via palmitoylation, specifically the involvement of the ZDHHC8/CAV1/lipid metabolism axis in CLL malignant proliferation, which could be a viable therapeutic target for CLL.

Daratumumab (Dara)-based regimens have been investigated in randomized controlled trials (RCTs) involving patients with newly diagnosed and previously untreated multiple myeloma (NDMM), but the optimal daratumumab-based regimen remains unclear. This study compares the efficacy of daratumumab-containing regimens for NDMM patients and explores optimal combinations. Databases were searched from inception until February 29, 2024. Trials comparing regimens with and without daratumumab, as well as their mutual comparisons, were included. Random effects models for serious adverse events (SAEs) and fixed effects models for other outcomes were utilized in both network meta-analysis (NMA) and component NMA (CNMA), with pooled effects estimated. The efficacy of all possible combinations of daratumumab with other drugs was assessed. A total of 17 trials were included, enrolling 7261 patients, of whom 2083 were treated with daratumumab. The optimal regimens for different outcomes were identified as follows: Dara-bortezomib (V)-melphalan (M)-corticosteroids (D) (Dara-VMD) showed the best results for both overall response rate (ORR) [RR = 1.97; 95

We conducted a systematic review and meta-analysis to evaluate the outcomes of Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in the treatment of Shwachman-Diamond syndrome (SDS). A literature search was performed on PubMed, Embase, and Web of Science. After screening 397 articles, 10 studies were included. Data was extracted in accordance with the PRISMA guidelines and analyzed using the R 'meta' package. The pooled median 3 (1-5)-year overall survival (OS) after Allo-HSCT were 63.7% (95% CI 56.9%-70.2%), 80.3% (95% CI 68.%5-92.1%), 41.1% (95% CI 21.7%-60.4%), 48.9% (95% CI 29.0%-68.9%), and 8.7% (95% CI 0.0%-60.8%) in SDS patients, SDS patients with bone marrow failure (BMF), SDS patients with myeloid neoplasms (MN), SDS patients with myelodysplastic syndrome (MDS), and SDS patients with acute myeloid leukemia (AML), respectively. Allo-HSCT is an efficacious approach for treating SDS patients with severe hematologic complications. However, poor outcomes were revealed in SDS patients with MN with a pooled 3 (1-5)-year relapse rate (RR) after Allo-HSCT of 25.8% (95% CI 12.5% - 39.0%), and a pooled 3-year non-relapse mortality (NRM) was 52.6% (95% CI 34.2%-70.9%). These findings were consistent with the clinical findings that transplant-related complications are the main cause of the poor transplantation prognosis of SDS patients with MN. Efficacious bone marrow conditioning regimens, graft-versus-host disease (GVHD) prevention, and bridging treatment regimens are potential means to improve the transplantation prognosis of SDS patients.

OBJECTIVE:To explore the early hemostatic mechanism of Jianpi Yiqi Shexue decoction (, JYSD) in treating immune thrombocytopathy (ITP), based on the functional homeostasis of brain-intestine axis and blood neurotransmitter METHODS: Non-drug treatment cases: Healthy volunteers were selected as normal control group and compared with patients with dysfunctional uterine bleeding, gastrointestinal tumors with bleeding and ITP, to detect the changes of blood 5-hydroxytryptamine (5-HT), β-endorphin (β-EP), vasoactive intestinal peptide (VIP) and compare the changes of blood neuro-transmitters in patients with different disease symptoms. Drug treatment cases: According to the randomized controlled multicenter clinical trial, 272 ITP patients were randomly divided into three groups: treatment group (JYSD) combined group (JYSD + Prednisone) control group (Prednisone). The changes of blood neuro-transmitter (5-HT, β-EP, VIP) before and after treatment were detected on the basis of peripheral blood platelet (PLT) and grade score. RESULTS:Non-drug treatment cases: compared with the normal control group, the 5-HT level was higher, and the VIP and β-EP levels were both lower in the ITP group (P < 0.001), and the 5-HT, VIP and β-EP levels in the Gastrointestinal tumors with bleeding group were also lower compared with the normal control group (P < 0.05, 0.001). Drug treatment cases: The PLT grading scores of the combination group and the control group after treatment were lower than that before treatment (P < 0.05, 0.001). The PLT grading score of the 3 groups were compared in pairs after treatment: the combination group was the lowest among the 3 groups, which was better than the treatment group, but no better than the control group (vs the treatment group, P = 0.005, vs the control group, P = 0.709). The statistical results of full analysis set (FAS) and per protocol set (PPS) were consistent. The bleeding symptom scores of the treatment and combination groups began to drop 7 d after treatment, and kept dropping 14 d after treatment until the end of the study (P < 0.05). On the other hand, the control group started to show favorable results 14 d after treatment (P < 0.05). The FAS and PPS analysis results were consistent. In the control group, the 5-HT level was higher and VIP level was lower after treatment, compared with those before treatment (P < 0.05, 0.001). The β-EP levels were both increased in the treatment and combination group after treatment, compared with those before treatment (P < 0.05). After treatment, the β-EP levels in the treatment and control groups were significantly lower compared with the combination groups (P < 0.05). After treatment, compared with the control group, the VIP levels in the treatment and combination groups were up-regulated, and the differences were statistically significant by rank sum test (P < 0.01), and by t-test (P = 0.0002, 0.0001). CONCLUSIONS:The prednisone tablet is better than the JYSD in increasing the level of PLT, while prednisone tablet combined with JYSD has more advantages in improving patients' peripheral blood PLT levels. However, in improving the bleeding time of ITP patients, the combination of the two drugs was significantly delayed compared with the single usage, showing the characteristics and advantages of traditional Chinese medicine. JYSD can regulate the neurotransmitter level of ITP patients through the function of the brain-gut axis, mobilize 5-HT in the blood of ITP patients to promote the contraction of blood vessels and smooth muscles, and activate the coagulation mechanism are the early hemostatic mechanisms of JYSD. Up-regulate the levels of β-EP and balancing VIP levels may be an important part of the immune mechanism of JYSD for regulating ITP patients.

In order to analyze the early death rate of APL and its associated factors, we selected 3212 APL patients from 1986 to 2015 in the SEER database, of which 683 (21.3%) patients were noted for early death. we found that the early death rate in APL has decreased over the past few years, and older age, lower socioeconomic status were major factors affecting early death. These findings could give insights for clinicians to elaborately assess the epidemiology and risk factors of early death in APL.Background: Early death is a major factor of treatment failure in acute promyelocytic leukemia (APL), however, the recent trends in the incidence of early death based on the population-level are not clear. Hence, this study is aimed at describing the incidence, recent trends, causes and character istics of ear ly death in APL based on the real world.Materials and Methods: APL patients diagnosed from 1986 to 2015 in the Surveillance, Epidemiology, and End Results (SEER) dataset were enrolled, and categorized based on gender, age, year of diagnosis, race, marital status, resident county and socioeconomic status (SES). The risk factors for all-cause and acute myelocytic leukemia (AML) specific early death were determined by univariate and multivariate logistic regression analyses, and stratified analysis was conducted by age.Results: Overall, 3212 APL patients were included in analysis between 1986 and 2015, of which a total of 683 (21.3%) patients were noted for early death. Significant differences were recognized for patient distribution by age, year of diagnosis, marital status, and SES. The early death rate of APL patients diagnosed during 2006-2015 was significantly lower than that of the early stage, but this trend was not evident in juvenile patients. At the same time, older age, and lower SES score were independent risk factors for early death in the multivariate analysis. Conclusion: We established that the early death trend in APL has decreased over the past few years, but the early death rate remains high, especially in older patients and those with lower SES.

Objective: To explore the hemostatic mechanism of Jianpi Yiqi Shexue decoction（JYSD） by regulating vascular factors in an immune thrombocytopenia（ITP） mouse model.Methods: An ITP mouse model was established by the passive-immune modeling method, and interventional drugs used were prednisone tablets and JYSD. The platelet count; vascular activity-related factors v WF, VCAM-1, and TM; and VEGF and b FGF were used as observational indicators.Results: On the 8th day of administration, compared with the model group, platelet counts in the prednisone and JYSD groups increased（both P ＜.001）. Compared with the control group, the levels of v WF, VCAM-1, and TM in the other groups were lower（all P ＜.05）. The VCAM-1 level in the JYSD group was higher than that in the prednisone group（P =.012）, but without significant difference compared with the model group（P =.051）. The TM level in the JYSD group was the lowest（vs. the model group,P =.047; vs. the prednisone group, P =.006）. Compared with the control group, the IOD values of VEGF and b FGF in the other three groups were lower（all P ＜.01）. The IOD values of VEGF in the prednisone and JYSD groups were both higher than those in the model group（P =.002 and P ＜.001, respectively）. The IOD values of b FGF among the model, prednisone, and JYSD groups were not statistically significant（P ＞.05）.Conclusion: A vascular factor disorder is involved in the pathogenesis of ITP. JYSD can increase the platelet count, upregulate VEGF expression, and reduce the TM level. JYSD has the same effect as prednisone tablets in regulating platelet, v WF, VEGF, and b FGF, with a stronger effect in normalizing VCAM-1 and TM levels. The hemostatic mechanism of JYSD is closely related to the effective balance of vascular factors.

目的 观察丹参酮Ⅱa对HL-60的凋亡与自噬以及相关因子水平的影响,探讨丹参酮Ⅱa抗急性髓系白血病的分子机制.方法 使用不同浓度的丹参酮Ⅱa处理HL-60细胞24、48 h后用CCK-8法检测增殖抑制率,吉姆萨染色观察细胞形态,Western blotting检测Caspase-3、Cleaved-Caspase-3、PARP-1、p-AMPK、p-mTOR、LC3B水平变化,联用自噬抑制剂巴弗洛霉素A1以CCK-8测细胞存活率.结果 以0、1、2、4、8、16、32、64、128 μmol/L丹参酮Ⅱa处理HL-60细胞24、48h后HL-60增殖被抑制,其作用随浓度增加和时间延长而加强,24、48 h的IC50分别为32.87、18.4 μmol/L;吉姆萨染色镜下观察见,随着药物浓度增加HL-60凋亡增加;Western blotting显示Caspase-3减少、Cleaved-Caspase-3增加,PARP-1切割增加,凋亡增强;p-AMPK增加、p-mTOR减少、LC3B增加,显示AMPK/mTOR自噬通路激活,联用巴弗洛霉素A1后丹参酮Ⅱa增殖抑制作用减弱.结论 丹参酮Ⅱa通过诱导HL-60凋亡和自噬发挥抗白血病作用,AMPK/mTOR可能是介导这一效应的重要信号通路.

基于目前中医药或中西医结合治疗急性髓细胞性白血病(AML)文献分析,并通过长期临床实践,提出"中医药防治AML一体化研究"概念与诊疗策略,主要内容包括:强化导致AML的前期疾病骨髓增生异常综合征(MDS)的治疗,以阻止或延缓疾病向AML转化;治疗复发难治或耐药AML,提高临床完全缓解率;控制AML相关症状或并发症,促进疾病康复;制定和优化以AML为中心的中医综合诊疗方案与康复计划,使更多的AML患者在诊疗过程中获益.但到目前为止,"中医药防治AML一体化研究"的重要性和临床应用价值尚未被高度重视,现有文献证据级别有限,很难形成被行业领域公认的专家共识或诊疗方案.因而,制定顶层设计方案,开展全国大协作的规范化临床研究是获得更多循证医学证据的关键,也是中医药治疗AML领域未来研究的重点.

目的 观察芪胶升白胶囊对结直肠癌术后化疗所致骨髓抑制的预防效果.方法 选取2016年1月-2018年6月河南中医药大学第一附属医院普外科收治的结直肠癌患者132例,按照随机数字表法将其分为对照组、治疗1组、治疗2组,各44例.3组均行开放或腹腔镜下结直肠癌根治术,术后2～3周采用mFOLFOX6方案序贯化疗,共8个周期.对照组仅采用上述治疗方案;治疗1组于首次化疗开始加服地榆升白片4片/次,3次/d;治疗2组于首次化疗开始加服芪胶升白胶囊4粒/次,3次/d.各组连续治疗至化疗周期结束.如出现严重骨髓抑制,可酌情选用人重组粒细胞集落刺激因子(rhG-CSF).比较治疗前后各组骨髓抑制分级、中医证候评分、Karnofsky(KPS)评分及rhG-CSF用量.结果 化疗结束后,两治疗组的骨髓抑制分级程度明显低于对照组(P＜0.05),KPS评分的改善、稳定病例数均优于对照组(P＜0.05),rhG-CSF使用量均少于对照组(P＜0.05),治疗2组中医证候评分低于对照组(P＜0.01).以上指标改善治疗2组均优于治疗1组(P＜0.01.P＜0.05).结论 芪胶升白胶囊可有效预防结直肠癌术后化疗骨髓抑制,减少rhG-CSF用量.

鼻咽癌是头颈部常见的恶性肿瘤之一,在中国南方最为常见.统计资料显示,全球的鼻咽癌患者70％～ 80％在我国.常见临床症状为鼻塞、涕中带血、耳闷堵感、听力下降、复视及头痛等. 由于鼻咽癌具有恶性程度高、易转移及早期症状不明显的特点,往往容易被人们忽视.一旦有了明显的自觉症状,多半已经进入了中晚期,难以救治.因此,对于疾病的早期预防至关重要.专家建议人们要关注以下几方面.

目的 观察益气维血胶囊联合西药补铁剂琥珀酸亚铁片治疗缺铁性贫血的临床效果.方法 选取2019年1月-2020年3月北京中医药大学东方医院、北京中医药大学东直门医院收治的缺铁性贫血患者80例为研究对象,以"随机数字表法"分组原则为主,将其分为试验组(40例)和对照组(40例).对照组单用琥珀酸亚铁片治疗,试验组给予益气维血胶囊联合琥珀酸亚铁片治疗.比较2组临床疗效,治疗前后红细胞数量(RBC)、血红蛋白(Hb)、血清铁蛋白(SF)、血清总铁结合力(TIBC)等血液检测指标水平变化,治疗后中医证候总治愈率及治疗期间不良反应(呕吐、腹泻、食欲不振等)发生情况.结果 治疗8周,2组均有较好的治疗效果,试验组总有效率为95.00％,高于对照组的80.00％(x2=4.114,P=0.043);治疗8周后,2组RBC、Hb、SF、TIBC水平较治疗前均有明显改善(P＜0.01),且试验组治疗后RBC、Hb、SF、TIBC水平均恢复到正常水平,恢复幅度较对照组更明显(P＜0.01);治疗8周,试验组中医证候总有效率为82.50％,高于对照组的52.50％(x2=8.205,P=0.004);2组不良反应发生率经统计学计算,差异不具有统计学意义(P＞0.05).结论 益气维血胶囊联合西药补铁剂琥珀酸亚铁片治疗缺铁性贫血临床疗效确切显著,患者的临床症状可快速恢复,不良反应较少,临床应用安全有效,具有较高的临床价值.

目的 探讨靛玉红及丹参酮Ⅱa联用促进雄黄降解突变型PMLA216T-RARα的作用机制.方法 用不同浓度雄黄作用于野生型及突变型PMLA216T-RARα,观察2组细胞PML-RARα降解作用,验证PMLA216T-RARα存在砷剂耐药.根据CCK8测出的IC50值确定各组分浓度,使用不同浓度、不同组合的雄黄、靛玉红、丹参酮Ⅱa作用于转染PMLA216T-RAR1α 细胞,应用蛋白质印迹法检测单用、两两联合及三者联合对PML-RARα的降解及自噬相关因子(p-mTOR、LC3B)的作用.分别联用蛋白酶体抑制剂卡非佐米及自噬抑制剂巴佛洛霉素A1,应用蛋白质印迹法检测各组细胞中PML-RARα的降解情况.结果 与对照组(不用药物干预)比较,雄黄浓度为0.5 μmol/L,作用于PML-RARα野生型及突变型PMLA216T-RARα 时,均使PML-RARα发生了明显降解(均P＜0.01),突变型PMLA216T-RARα表达的PML-RARα均比野生型高(均P＜0.01).与对照组比较,雄黄4μmol/L、靛玉红8umol/L、丹参酮Ⅱa 8 μmol/L作用于PMLA216T-RARα时,均使PML-RARα发生降解(均P＜0.01),可降低p-mTOR水平(均P＜0.01),升高LC3B水平(P＜0.05,P＜0.01),雄黄+丹参酮Ⅱa+靛玉红三者联合时上述作用最强(P＜0.01).与对照组比较,雄黄+丹参酮Ⅱa+靛玉红、雄黄+丹参酮Ⅱa+靛玉红+卡非佐米联用作用于PMLA216T-RARα时,均使PML-RARα发生明显降解(均P＜0.01);与对照组比较,单用卡非佐米、单用巴佛洛霉素A1、雄黄+丹参酮Ⅱa+靛玉红+巴佛洛霉素A1,作用于PMLA216T-RARα时,均使PML-RARα发生了明显蓄积,且雄黄+丹参酮 Ⅱa+靛玉红+巴佛洛霉素A1组PML-RARα表达高于单用卡非佐米及单用巴佛洛霉素A1组(均P＜0.01).结论 靛玉红及丹参酮Ⅱa联用可通过自噬增强雄黄对突变型PMLA216T-RARα的降解作用,三者联用自噬作用最强,可能为复方黄黛片治疗急性早幼粒细胞白血病的作用机制之一.

恶性血液病是指各型急慢性白血病、淋巴瘤、骨髓增生异常综合征、骨髓增殖性肿瘤、多发性骨髓瘤等血液系统恶性肿瘤.化疗是大多数恶性血液病的常规治疗手段,但化疗药物在杀伤肿瘤细胞的同时也会杀伤人体的正常细胞,引起一系列不良反应的发生.胃气是中医基础理论的一个重要概念,脾胃为"后天之本",气血生化之源,气机升降之枢纽,且与他脏有密切联系,而胃气是脾胃功能的重要体现,探讨"有胃气则生"理论在临床中的应用有重要意义.脾胃亏虚是恶性血液病化疗患者的重要病因,是肿瘤发病的重要因素,化疗导致恶性血液病患者脾胃虚弱加重.调理脾胃、顾护胃气在恶性血液病化疗中具有重要作用.化疗前期,以理气祛邪为主,兼以顾护胃气;化疗期,扶正祛邪,调理脾胃;化疗后期,扶正培本,恢复胃气.中西医结合疗效更佳.临床应结合辨证遣药组方,药物宜纯、宜平,分量宜轻,避免使用大辛大热、大苦大寒、大补大泻等伤脾败胃之品.

白血病(leukemia)是造血干细胞克隆性疾病,是一组高度异质性的恶性血液病,其特点为白血病细胞异常增生、分化成熟障碍,并伴有凋亡减少. 根据细胞成熟障碍阻滞在不同阶段,阻滞发生在较早阶段称为急性白血病(AL),阻滞在较晚阶段称为慢性白血病(CL).有时也用自然病病程分类,6个月内为急性白血病,6～ 12个月为亚急性白血病,12个月以上为慢性白血病.

目的 观察益气维血胶囊治疗贫血性眩晕临床疗效.方法 将80例缺铁性贫血患者随机分为对照组(40例)和试验组(40例).对照组采用琥珀酸亚铁片治疗,试验组采用益气维血胶囊治疗,比较两组病例治疗后疾病疗效、眩晕疗效与中医证候(症状与体征)疗效.结果 ①疾病疗效:两组病例显效率(治愈+有效)分别为95％(试验组)、82.5％(对照组),两组比较,无统计学意义(P>0.05),两组病例疗效相等.②眩晕疗效:两组病例显效率(治愈+有效)与总有效率分别为62.5％、97.5％(试验组)与50％、82.5％(对照组),两组病例眩晕疗效比较,有统计学意义(P<0.05).试验组优于对照组.③证候(症状与体征)总疗效:两组病例显效率(治愈+有效)与总有效率分别为50.0％、97.5％(试验组)与50％、72.5％(对照组),两组病例证候(症状与体征)疗效比较,有统计学意义(P<0.05).试验组优于对照组.结论 益气维血胶囊联合琥珀酸亚铁除对缺铁性贫血具有良好的治疗效果外,眩晕与证候(症状与体征)总疗效明显优于琥珀酸亚铁对照组,体现了益气维血胶囊治疗缺铁性贫血特点与优势.

目的 探索健脾益气摄血方治疗免疫性血小板减少症(ITP)的效应及机制.方法 采用中央随机对照、多中心临床试验方法,纳入272例免疫性血小板减少症脾不统血证患者.其中,健脾益气摄血方组104例、健脾益气摄血方联合强的松组(联合组)103例、强的松组65例.共治疗21 d,每周访视1次,统计止血、血小板数值以及中医证候(单项症状)疗效;检测外周血象变化、凝血功能变化、与免疫相关的血液神经递质变化、血小板活化功能与NK细胞分子标志物表达比例.结果 治疗后各组出血程度均较治疗前减轻,健脾益气摄血方组、联合组的疗效早于强的松组出现.治疗后各组血小板减少程度评分较治疗前减少,疗效优势为联合组>强的松组>健脾益气摄血方组.健脾益气摄血方组、联合组中医证候总疗效优于强的松组(P<0.05).各组各项中医证候评分优于治疗前.在食后腹胀评分上,健脾益气摄血方组与联合组的疗效出现早于强的松组.各组血小板计数均较治疗前升高,联合组与强的松组高于健脾益气摄血方组(P<0.05).强的松组凝血酶原时间小于健脾益气摄血方组.健脾益气摄血方组、联合组疗后β-内啡肽测定值较治疗前均升高.3组治疗后血管活性肠肽均较治疗前下降.结论 健脾益气摄血方能够有效改善"脾不统血证"ITP患者的出血症状,提升患者外周血小板计数,可有效改善ITP患者中医证候与单项症状.其疗效机制可能与调节脑-肠轴的肽类神经递质有关.

目的:观察健脾益气摄血颗粒改善“脾不统血证(脾气虚)”型免疫性血小板减少症(ITP)患者症状及止血疗效.方法:应用中央随机对照、多中心临床试验方法,将符合病例入选标准的ITP患者按3∶3∶2分为中药组(健脾益气摄血组)、联合组(健脾益气摄血联合强的松组)、西药组(强的松).治疗21d,每周访视1次,采集症状与出血等数据,最后进行统计学处理.结果:临床症状疗效中药组(104例)、联合组(103例)在临床证候显效率与有效率明显优于西药组(P＜0.05),治疗7d后出血程度较入组时明显减轻(P＜0.05),中药组的血小板均值及增长趋势始终低于其他两组(P＜0.05).结论:健脾益气摄血颗粒在改善“脾不统血”ITP患者的脾(气)虚症状及出血症状上,疗效优于并早于单用强的松;联合用药优势更加明显,并且对强的松可能潜在的不良反应有一定的缓解作用.

目的 了解北京地区老龄人群血清铁蛋白代谢情况,为进一步防治铁代谢紊乱提供依据.方法 由北京中医药大学东直门医院、北京市东城区新中街卫生服务站、北京市东城区十字坡卫生服务站、北京市东城区外交部街卫生服务站、北京市海淀区中国气象局卫生服务站进行人群筛选后,空腹抽取3ml静脉血,2小时内送检,对铁蛋白结果进行统计学分析.结果 在5576份检测报告中:①有366份血清铁蛋白<12μg/L,男性、女性之间血清铁蛋白减少检出率无差异(P>0.05);②有1055份血清铁蛋白>400μg/L,男性血清铁蛋白与女性比较差异有显著性(P=0.00),且女性血清铁蛋白增高与年龄相关(P=0.006),以75～84岁年龄段检出率最高.结论 北京地区老龄人群血清铁蛋白异常现象应加以高度关注,针对其特点制订预防措施.

肿瘤相关抑郁是指在对肿瘤进行诊断、治疗及其合并症处理等过程中产生的导致患者失去个人精神常态的病理性情绪反应.肿瘤诊治过程可导致患者情绪障碍,而抑郁情绪又会促进肿瘤的发生、发展、复发和转移,二者互为因果[1-4].肿瘤相关抑郁国外发病率为3.7% ~58%,国内发生率高达25% ~75% [5].部分躯体症状,如疼痛、失眠常被肿瘤自身症状所掩盖,仅有不足10%的患者得到确诊,甚至可能导致肿瘤的治疗过程的终止[6,7].